Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free. Our insightful and holistic reports have helped corporates, academia and researchers take their research forward. You also agree to receive email updates from us on our new reports and solutions.

AbbVie SWOT & PESTLE Analysis

ID : 52538953| Nov 2020| 15 pages

COMPANY PROFILE -AbbVie

Business Sector :Bio-pharmaceutical

Operating Geography :Lake Bluff, Illinois, USA, North America, Europe, Worldwide

About AbbVie :

AbbVie is a bio-pharmaceutical multinational founded in 2013 as a spin-off from Abbot. It manufactures a wide range of pharmaceutical products which are mainly instrumental in the treatment of diseases like HIV, HCV, Parkinson’s disease, thyroid diseases, cancer etc. It has a worldwide presence consisting of nearly 30,000 employees as of January 2020, which includes scientists, manufacturing experts, and researchers. The company has taken upon itself the onus of curing seemingly ‘incurable’ diseases so that it ultimately creates a positive impact on the lives of the patients. Organizations like ‘World’s Best Workplaces’, ‘ROBECOSAM’, ‘FTSE4Good’ and ‘Fortune 100 Best Companies to Work for’ have recognized AbbVie for their monumental effort to create a healthier world and care for stakeholders.
AbbVie's mission as per their website is to "Create an innovation-driven, patient-focused specialty biopharmaceutical company capable of achieving sustainable top-tier performance through outstanding execution and a consistent stream of innovative new medicines." The USP of Abbvie lies in its innovative capabilities which led to the development of the drug Humira and made the company a global pharma giant.

AbbVie Revenue :


US$ 33,266 million - FY ending 31st December 2019 (Y-O-Y growth of + 1.5%)
US$ 32,753 million - FY ending 31st December 2018

Competitive Analysis of AbbVie

SWOT
PESTLE
The SWOT analysis of Abbvie is presented below in a matrix followed by detailed analysis
Strengths
Weaknesses
1. Strong manufacturing capabilities
2. Diversified products and innovation
3. Strong supplier relations and reliability
4. Sustainable supply chain
5. Strong technological capabilities
6. Robust pipeline growth and development
1. Public relations issues
2. High reliance on revenues from Humira
3. Weak corporate governance
Opportunities
Threats
1. Remarkable growth potential
2. Benefits from new tax reforms
3. Emerging pharmaceutical market
1. Threats from biosimilars
2. Competition in the pharma segment
3. Government Regulations regarding Medicare/Medicaid payments
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments
On purchase, the report will reach your email inbox within minutes. At rare times, a slight delay not exceeding 4 hours might be caused.

Detailed SWOT Analysis of AbbVie

 

Strength

1. Strong manufacturing capabilities: AbbVie has 10 state-of-the-art manufacturing facilities throughout Europe and North America. They also provide various contract production facilities throughout the globe. Their manufacturing capabilities include Biology, Potent drugs, HM Extrusion, Prefilling of syringes, Fermentation, etc. as well as custom manufacturing services. Moreover, AbbVie has a highly experienced and skilled workforce who has undergone various types of trainings which has increased their motivation and focus to excel at their work. With the opening of its first phase of global manufacturing facility at Singapore, AbbVie wishes to expand its horizon of operations for biologics and small molecule manufacturing – also known as the API facility. The company’s oncology and women’s health areas will be greatly benefitted through this modern facility. This is also AbbVie’s first venture into manufacturing in Asia and is expected to be up and running by the end of 2018. With a skilled pool of talent, AbbVie wishes to leverage its workforce’s technical expertise to provide value to their customers and stakeholders worldwide. Abbvie has partnerships with biotech, universities, nonprofits, and government organizations and it uses its 22 State-of-the-art R&D and manufacturing centers to help further the development of science.

2. Diversified products and innovation: Ever since its inception, AbbVie has been aiming at developing a lot of diverse products by leveraging its skilled and experienced workforce through innovation. AbbVie makes sure that its medicines perform well not only in their laboratories but also in every sphere of one’s life so that patients are benefitted overall. The company wishes to eliminate various chronic and hard to cure diseases like Alzheimer’s disease, various types of cancer and other immune-mediated conditions. Humira, which is Abbvie’s most important product, is difficult to develop, as it is a biologic. This means that it is not made of synthetic chemicals, but rather from living cells. Moreover, biosimilars, which are copies of biologic drugs, are also harder to recreate than normal generic drugs. These factors along with an aggressive patent strategy have made it possible for AbbVie to fend of its competitors. AbbVie is also focusing on areas to produce path-breaking discoveries in medicine which are used in the treatments of immunology, oncology, neuroscience, virology and general medicine. They have also a number of products in their pipeline like investigational drugs which are currently under study and not yet approved by the FDA. Their approved drugs are also under study to be used in newer applications for which they have yet not been approved.

3. Strong supplier relations and reliability: AbbVie has a robust set of suppliers who share the same mission, vision and commitment to innovation and improve the health of patients across the world. AbbVie ensures that their suppliers meet the quality requirements by working closely with them. This is done by monitoring and helping the suppliers enhance their execution based on various clearly defined and stringent metrics. This ensures a learning experience of both AbbVie and its suppliers which they put to use subsequently. AbbVie conducts performance reviews and audits to make sure that the products supplied are of high quality and meet technical, safety and quality standards. All suppliers are stringently required to follow a ‘Supplier Code of Conduct’. Abbvie, by strategically implemented actions and proper assessments of the supply chain, is also able to ensure that customers always have a continuous supply of its products. They utilize various Supplier Risk Management techniques to sustain their business for both the stakeholders and themselves.

The remaining section of “Strength” is available only in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

This section is available only in the 'Complete Report' on purchase.

Threat

This section is available only in the 'Complete Report' on purchase.

Major Brands :

  • Humira
  • Imbruvica
  • Venclexta
  • Zinbryta

Key Business Segments / Diversification :

AbbVie
Immunology Oncology Virology
Neuroscience
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments
On purchase, the report will reach your email inbox within minutes. At rare times, a slight delay not exceeding 4 hours might be caused.

Check Out Analysis of Other Relevant Companies

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
References used in AbbVie Analysis Report

1. Abbvie Quaterly finacial report 2020 - https://investors.abbvie.com/static-files/b85f33a6-92de-4ba7-b722-e9ba55a98a54

2. Abbvie annual report 2019 - https://investors.abbvie.com/static-files/19b29be9-9b2a-4915-9a85-1e6344a06863

3. How AbbVie is bringing antiviral expertise to the COVID-19 battle - https://stories.abbvie.com/stories/how-abbvie-is-bringing-antiviral-expertise-to-covid-19-battle.htm

4. About the company – Abbvie - https://www.abbvie.com/our-company.html?_ga=2.216047582.953854711.1606301338-231677307.1606301338

5. AbbVie J.P. Morgan Healthcare Conference 2019: https://investors.abbvie.com/static-files/63833f8e-738b-4ffa-b1ad-1e956816f9d1

The detailed complete set of references are available on request in the 'Complete report' on purchase.

How to Reference This Page?

You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.

AbbVie SWOT & PESTLE Analysis - SWOT & PESTLE.COM

SWOT & PESTLE.com (2020). AbbVie SWOT & PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/abbvie/ [Accessed 05 Dec, 2020].

In-text: (SWOT & PESTLE.com, 2020)

Copyrights and Disclaimer

Abbvie SWOT and PESTLE analysis has been conducted by Rajarshi Mondal and reviewed by senior analysts from Barakaat Consulting.

Copyright of Abbvie SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.

You might also like to check out :
AbbVie SWOT & PESTLE Analysis
Price : USD 12.53